Biomarkers for drug development: The time is now!

Clinical and Statistical Considerations in Personalized Medicine

Volumn , Issue , 2014, Pages 1-26

  Carini, Claudio ^a   Seyhan, Attila ^b,c,d  

^a PFIZER INC   (United States)

^b FLORIDA HOSPITAL   (United States)

^c BURNHAM INSTITUTE   (United States)

^d Massachusetts Institute of Technology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85054398914     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b16749     Document Type: Chapter

References (43)

1. Alevizos, I. and G. G. Illei 2010. MicroRNAs as biomarkers in rheumatic diseases. Nat Rev Rheumatol 6(7): 391-398.
2. Atkins, M. et al. 2005. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 11(10): 3714-3721.
3. Bayele, H. K., A. Chiti et al. 2010. Isotopic biomarker discovery and application in translational medicine. Drug Discov Today 15(3-4): 127-136.
4. Burczynski, M. E. and A. J. Dorner 2006. Transcriptional profiling of peripheral blood cells in clinical pharmacogenomic studies. Pharmacogenomics 7(2): 187-202.
5. Butterfield, L. H., M. L. Disis et al. 2008. A systematic approach to biomarker discovery; preamble to “the iSBTc-FDA taskforce on immunotherapy biomarkers”. J Transl Med 6: 81.
6. Calvano, S. E., W. Xiao et al. 2005. A network-based analysis of systemic inflammation in humans. Nature 4377061: 1032-1037.
7. Fathman, C. G., L. Soares et al. 2005. An array of possibilities for the study of autoimmunity. Nature 435(7042): 605-611.
8. Galon, J. et al. 2006.Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science, 313(5795): 1960-1964.
9. Hamilton, W. F. and D. W. Richards, 1982. The output of the heart. In: Fishman, A. P. and D. W. Richards (eds). American Physiological Society, Bethesda, MD, 83-85.
10. Himmelfarb, J., P. Stenvinkel et al. 2002. The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62(5): 1524-1538.
11. Holmgren, E. 2008. Quantifying the usefulness of PD biomarkers in Phase 2 screening trials of oncology drugs. Stat Med 27(24): 4928-4938.
12. Hughes, M.D. et al. 1998. CD4 cell count as a surrogate endpoint in HIV clinical trials: A meta-analysis of studies of the AIDS Clinical Trials Group. AIDS 12(14): 1823-1832.
13. Janeway, H. H. 1913. Intratracheal anaesthesia: A. By nitrous oxide and oxygen. B. By nitrous oxide and oxygen under conditions of differential pressure. Ann Surg 58(6 Suppl): 927-933.
14. Katz, L. N. and H. K. Hellerstein 1982. Electrocardiography. In: Fishman, A. P., Richards D. W. (eds). American Physiological Society, Bethesda, MD, 83-85.
15. Kotz, K. T., W. Xiao et al. 2010. Clinical microfluidics for neutrophil genomics and proteomics. Nat Med 16(9): 1042-1047.
16. Laudanski, K., C. Miller-Graziano et al. 2006. Cell-specific expression and pathway analyses reveal alterations in trauma-related human T cell and monocyte pathways. Proc Natl Acad Sci USA 103(42): 15564-15569.
17. Lee, J. W., V. Devanarayan et al. 2006. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res 23(2): 312-328.
18. Lind, L. 2003. Circulating markers of inflammation and atherosclerosis. Atherosclerosis 169: 203-214.
19. Mattes, W. B. et al. 2010. Research at the interface of industry, academia and regulatory science. Nat Biotechnol 28(5): 432-433.
20. National High Blood Pressure Education Program, Task Force I: Report to the Hypertension Information and Education Advisory Committee. Recommendations for a national high blood pressure data base for effective antihypertensive therapy. 1973. U.S. Department of Health, Education and Welfare Publication No. (NIH) 74-593. Washington, DC: Government Printing Office.
21. Nevins, J. R. and A. Potti 2007. Mining gene expression profiles: Expression signatures as cancer phenotypes. Nat Rev Genet 8(8): 601-609.
22. Nishimura, K., D. Sugiyama et al. 2007. Meta-analysis: Diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 146: 797-808.
23. Panelli, M.C. et al. 2007. Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome Biol 8(1): R8.
24. Pearson, T. A., Mensah, G. A. et al. 2003. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107: 499-511.
25. Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC I). 1977. JAMA 237: 255-261.
26. Ridker, P. M., J. E. Buring, N. R. Cook, N. Rifai 2003. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8-year follow-up of 14 719 initially healthy American women. Circulation 107: 391-397.
27. Ridker, P. M., M. Cushman, M. J. Stampfer, R. R. Tracy, C. H. Hennekens 1997. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336: 973-979.
28. Rifai, N. and R. E. Gerszten 2006. Biomarker discovery and validation. Clin Chem 52(9): 1635-1637.
29. Rifai, N., M. A. Gillette et al. 2006. Protein biomarker discovery and validation: The long and uncertain path to clinical utility. Nat Biotechnol 24(8): 971-983.
30. Riva-Rocci, S. 1896. Un nuovo sfigmomanometro. Gazetta medica di torino 47: 981-996;1001 1017.
31. English translation: Faulconer, A. Jr, Keys, T. E. (eds.) 1965. Foundations of Anesthesiology, Vol. 2. Springfield, IL: Charles C. Thomas, 1043-1075.
32. Sabatino, M. et al. 2009. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol 27(16): 2645-2652.
33. Schulte-Pelkum, J., M. Fritzler, and M. Mahler 2009. Latest update on the Ro/SS-A autoantibody system. Autoimmun Rev 8(7): 632-637.
34. Shen, B. and Hwang, J. 2010. The clinical utility of precision medicine: Properly assessing the value of emerging diagnostic tests. Clinical Pharmacology & Therapeutics 88(6): 754-756.
35. Sistare, F.D. et al. 2010. Towards consensus practices to qualify safety biomarkers for use in early drug development. Nat Biotechnol 28(5): 446-454.
36. Vertes, V., L. Tobias, and S. Galvin 1991. Historical reflections on hypertension. Prim Care 18(3): 471-482.
37. Wagner, J. A. 2002. Overview of biomarkers and surrogate endpoints in drug development. Dis Markers 18(2): 41-46.
38. Wagner, J. A., S. A. Williams et al. 2007. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther 81(1): 104-107.
39. Winkler, H., 2010. Biomarkers in the development of novel medicines for the treatment of cancer. Europena Pharmaceutical Review, 2010(3).
40. Woodcock, J. and R. Woosley 2008. The FDA critical path initiative and its influence on new drug development. Annu Rev Med 59: 1-12.
41. Woosley, R. L. and J. Cossman 2007. Drug development and the FDA’s Critical Path Initiative. Clin Pharmacol Ther 81(1): 129-133.
42. Zhang, L. et al. 2003. Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinoma. Clin Cancer Res 9(1): 264-272.
43. Zwierzina, H. 2008. Biomarkers in drug development. Ann Oncol 19 (Suppl 5): v33-37.